Zydus Life shares jump up to 5% after Q3 revenue rises 30% to Rs 6,865 crore

Zydus Lifesciences share price

• Zydus Lifesciences Q3 net profit rose 2 percent YoY to Rs 1,042 crore
• Revenue jumped over 30 percent YoY to Rs 6,864.5 crore in Q3 FY26
• Shares surged 5 percent intraday, closing 4 percent higher at Rs 922

Did our AI summary help?

The shares of Zydus Lifesciences jumped around 5 percent on February 9 after the company released its results for the October-December quarter of the financial year 2026.

The shares of the company rose to an intraday high of Rs 933.35 apiece, the highest level seen by the stock in over a month. The pharma stock later pared some gains to close at Rs 922 apiece (around 4 percent up).

Zydus Life Q3 Results:

Zydus Lifesciences today reported a consolidated net profit of Rs 1,042 crore for the third quarter of FY26, marking a nearly 2 percent year-on-year (YoY) rise from the Rs 1,023.5 crore net profit reported in the corresponding quarter of the previous financial year.

This however includes a one-time exceptional cost of Rs 84.9 crore arising out of the implementation of the new labour codes, which became effective last year.

The pharma major’s revenue from operations meanwhile rose more than 30 percent YoY to Rs 6,864.5 crore in Q3 FY26 from Rs 5,269.1 crore in Q3 FY25.

Zydus Life reported a 30.9 percent YoY rise in EBITDA to Rs 1,816.4 crore during the quarter under review, while EBITDA margin improved slightly to 26.5 percent in Q3 FY26 from 26.3 percent in Q3 FY25.

“Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation. Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value,” said Sharvil Patel, Managing Director at Zydus Lifesciences Limited.

Zydus Life share price:

Zydus Lifesciences shares have gained more than 2 percent in the past five days, and over 3 percent in the past one month. The stock has however fallen 3.5 percent in the past six months, and over 4 percent in the past one year.

The stock currently has a P/E ratio of around 18, and a market capitalization of Rs 92,775 crore.

Follow all updates from the stock markets here.